Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

35604 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained .The aims of the post hoc analyses are:

To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use, crude and adjusted by confounding.

To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex.

To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death

NCT01360047

Nonfatal Myocardial Infarction Coronary Death

COMPLETED

Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death

NCT01360073

Nonfatal Myocardial Infarction Coronary Death

COMPLETED

The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users

NCT01814943

Uncomplicated Peptic Ulcer

COMPLETED

Pharmacodynamic-pharmacokinetic Trial, of Slow Release ASA, in the Platelet Functionalism.

NCT00425074

Cardiovascular Disease

COMPLETED PHASE1

Risk of Uncomplicated Peptic Ulcer in the General Population

NCT01888588

Peptic Ulcer [Iowa Type (107680.0010)]

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin discontinuers; Aspirin non-discontinuers

Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin

Risk of low dose aspirin discontinuation

Intervention Type DRUG

PPI continuous use; No PPI usePPI

Drug

PPI continuous use; No PPI use

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Risk of low dose aspirin discontinuation

PPI continuous use; No PPI usePPI

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 50-84 years in 2000-2007.
* Patients with first prescription of low dose ASA ( see study population description).
* Patients were required to have been enrolled with their primary care practitioner (PCP) for at least 2 years and to have a computerized prescription history of at least 1 year before the start of the study.

Exclusion Criteria

* Patients aged below age 50 and 85 years and above ( see study population description).
* Patients with a diagnosis of cancer, alcohol abuse or alcohol-related disease.
* Incomplete data recording in THIN.

Minimum Eligible Age

50 Years

Maximum Eligible Age

84 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No